The Opioid Growth Factor Inhibits Established Ovarian Cancer in Nude Mice and Can Be Combined with Taxol or Cisplatin to Enhance Growth Inhibition

Renee N. Donahue, Ian S. Zagon, Patricia J. McLaughlin

.
Department of Neural and Behavioral Sciences, The Pennsylvania State University, College of Medicine, Hershey PA,.

DOI: 10.4236/jct.2011.22013                

Abstract

Ovarian cancer is the 5th leading cause of cancer-related mortality in women. Seventy-five percent of ovarian cancer patients present in advanced stages, and receive cytoreductive surgery and adjuvant chemotherapy. However, within 2 years 65% of these patients relapse and thereafter only receive palliative care. Novel therapies based on the biology of these cancers are urgently needed. The opioid growth factor (OGF)-OGF receptor (OGFr) axis is an endogenous opioid system known to inhibit proliferation of human ovarian cancer cells in tissue culture, but does not affect cell survival. The present study determined whether OGF in combination with standard of care chemotherapy, provides an inhibitory effect on the growth of human ovarian cancer cells in vitro. In addition, this investigation assessed whether OGF biotherapy, alone or in combination with taxol or cisplatin, inhibits tumor growth in mice with xenografts of ovarian cancer. The combination of OGF (10–6 M) with taxol (10–9 M or 10–10 M) or cisplatin (0.01 ug/ml or 0.001 ug/ml) markedly reduced cell number and DNA synthesis in vitro to a greater extent than individual compounds. OGF, but not taxol or cisplatin, altered growth in an opioid receptor mediated and reversible manner. Female nu/nu mice inoculated subcutaneously with SKOV-3 cells, and treated with OGF (10 mg/kg) for 5 weeks commencing at the time tumors became measurable, had tumor volumes and weight that were reduced by up to 50% from animals receiving saline. The combination of OGF with taxol (3 mg/kg, weekly) or cisplatin (4 mg/kg, weekly for 2 weeks) for 37 days reduced tumor volumes and weight in contrast to mice receiving individual agents alone. Moreover, OGF treatment in mice receiving cisplatin provided protection against the weight loss associated with cisplatin alone. All treatments suppressed DNA synthesis and angiogenesis, whereas exposure to taxol or cisplatin, but not OGF, induced apoptosis. Additive inhibitory effects on DNA synthesis and angiogenesis were recorded in animals treated with both OGF and taxol, or OGF and cisplatin, in comparison to individual compounds alone. OGF and OGFr were detected in tumor tissue; however OGFr expression was reduced 51% - 81% by OGF treatment. This preclinical evidence demonstrates that OGF biotherapy markedly inhibits ovarian tumorigenesis in a non-toxic manner, and can be combined with taxol or cisplatin to provide an enhanced therapeutic benefit.

Keywords

Cell Proliferation, [Met⁵]-Enkephalin, Opioid Growth Factor, OGFr, Ovarian Cancer

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	P. Dinh, P. Harnett, M. J. Piccart-Gebhart and A. Awada, “New Therapies for Ovarian Cancer: Cytotoxics and Molecularly Targeted Agents,” Critical Reviews in Oncology/Hematology, Vol. 67, No. 2, August 2008, pp. 103-112. doi:10.1016/j.critrevonc.2008.01.012
[2]	A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman, “Global Cancer Statistics,” CA: A Cancer Journal for Clinicians, Vol. 61, No. 2, February 2011, pp. 69-90. doi:10.3322/caac.20107
[3]	I. Boger-Megiddo and N. S. Weiss, “Histologic Subtypes and Laterality of Primary Ovarian Tumors,” Gynecologic Oncology, Vol. 97, No. 1, April 2005, pp. 80-83.doi:10.1016/j.ygyno.2004.11.054
[4]	N. Chobanian and C. S. Dietrick, “Ovarian Cancer,” Surgical Clinics of North America, Vol. 88, No. 2, April 2008, pp. 285-299. doi:10.1016/j.suc.2007.12.002
[5]	E. J. Nam and Y. T. Kim, “Alteration of Cell-Cycle Regulation in Epithelial Ovarian Cancer,” International Journal of Gynecological Cancer, Vol. 18, No. 6, November-December 2008, pp. 1169-1182.
[6]	I. S. Zagon, M. F. Verderame and P. J. McLaughlin, “The Biology of the Opioid Growth Factor Receptor (OGFr),” Brain Research Reviews, Vol. 38, No. 3, February 2002, pp. 351-376. doi:10.1016/S0165-0173(01)00160-6
[7]	P. J. McLaughlin, R. J. Levin and I. S. Zagon, “Regulation of Human Head and Neck Squamous Cell Carcinoma Growth in Tissue Culture by Opioid Growth Factor,” International Journal of Oncology, Vol. 14, No. 5, May 1999, pp. 991-998.
[8]	I. S. Zagon, J. P. Smith and P. J. McLaughlin, “Human Pancreatic Cancer Cell Proliferation in Tissue Culture is Tonically Inhibited by Opioid Growth Factor,” International Journal of Oncology, Vol. 14, No. 3, March 1999, pp. 577-584.
[9]	I. S. Zagon, S. D. Hytrek and P. J. McLaughlin, “Opioid Growth Factor Tonically Inhibits Human Colon Cancer Cell Proliferation in Tissue Culture,” American Journal of Physiology, Vol. 271, No. 3, Part 2, September 1996, pp. R511-R518.
[10]	G. J. Bisignani, P. J. McLaughlin, S. D. Ordille, M. J. Jarowenko and I. S. Zagon, “Human Renal Cell Proliferation in Tissue Culture is Tonically Inhibited by Opioid Growth Factor,” Journal of Urology, Vol. 162, No. 6, December 1999, pp. 2186-2191.doi:10.1016/S0022-5347(05)68157-8
[11]	R. N. Donahue, P. J. McLaughlin and I. S. Zagon, “Cell Proliferation of Human Ovarian Cancer is Regulated by the Opioid Growth Factor—Opioid Growth Factor Receptor Axis,” American Journal of Physiology-Regulatory Integrative and Comparative Physiology, Vol. 296, No. 6, June 2009, pp. R1716-R1725. doi:10.1152/ajpregu.00075.2009
[12]	F. Cheng, I. S. Zagon, M. F. Verderame and P. J. McLaughlin, “The Opioid Growth Factor (OGF)-OGF Receptor Axis Utilizes the P16 Pathway to Inhibit Progression of Human Squamous Cell Carcinoma of the Head and Neck,” Cancer Research, Vol. 67, No. 21, November 2007, pp. 10511-10518.
[13]	F. Cheng, P. J. McLaughlin, M. F. Verderame and I. S. Zagon, “The OGF-OGFr Axis Utilizes the P21 Pathway to Restrict Progression of Human Pancreatic Cancer,” Molecular Cancer, Vol. 7, No. 5, January 2008, pp. 5-17.
[14]	F. Cheng, P. J. McLaughlin, M. F. Verderame and I. S. Zagon, “The OGF-OGFr Axis Utilizes the P16ink4a and P21waf1/CIP1 Pathways to Restrict Normal Cell Proliferation,” Molecular Biology of the Cell, Vol. 20, No. 1, January 2009, pp. 319-327.doi:10.1091/mbc.E08-07-0681
[15]	I. S. Zagon and P. J. McLaughlin, “Opioids and the Apoptotic Pathway in Human Cancer Cells,” Neuropeptides, Vol. 37, No. 2, April 2003, pp. 79-88. doi:10.1016/S0143-4179(03)00007-6
[16]	I. S. Zagon, M. F. Verderame, S. S. Allen and P. J. McLaughlin, “Cloning, Sequencing, Chromosomal Location, and Function of a Cdna Encoding the Opioid Growth Factor Receptor (Ogfr) in Humans,” Brain Research, Vol. 856, No. 1-2, February 2000, pp. 75-83. doi:10.1016/S0006-8993(99)02330-6
[17]	F. Cheng, P. J. McLaughlin, M. F. Verderame and I. S. Zagon, “Dependence on Nuclear Localization Signals of the Opioid Growth Factor Receptor in the Regulation of Cell Proliferation,” Experimental Biology and Medicine, Vol. 234, No. 5, May 2009, pp. 532-541. doi:10.3181/0901-RM-16
[18]	I. S. Zagon, T. B. Ruth, A. E. Leure-duPree, J. W. Sassani and P. J. McLaughlin, “Immunoelectron Microscopic Localization of the Opioid Growth Factor Receptor (Ogfr) and OGF in the Cornea,” Brain Research, Vol. 967, No. 1-2, March 2003, pp. 37-47.doi:10.1016/S0006-8993(02)04172-0
[19]	I. S. Zagon, T. B. Ruth and P. J. McLaughlin, “Nucleocytoplasmic Distribution of Opioid Growth Factor (OGF) and Its Receptor (Ogfr) in Tongue Epithelium,” The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, Vol. 282, No. 1-2, March 2005, pp. 24-37.
[20]	F. Cheng, P. J. McLaughlin and I. S. Zagon, “Regulation of Cell Proliferation by the Opioid Growth Factor is Dependent on Karyopherin Beta and Ran for Nucleocytoplasmic Trafficking,” Experimental Biology and Medicine, Vol. 235, No. 9, September 2010, pp. 1093-1101. doi:10.1258/ebm.2010.010139
[21]	I. S. Zagon, R. N. Donahue and P. J. McLaughlin, “Opioid Growth Factor—Opioid Growth Factor Receptor Axis is a Physiological Determinant on Cell Proliferation in Diverse Human Cancers,” American Journal of Physiology-Regulatory Integrative and Comparative Physiology, Vol. 297, No. 4, October 2009, pp. R1154-R1161. doi:10.1152/ajpregu.00414.2009
[22]	I. S. Zagon, P. J. McLaughlin, S. R. Goodman and R. E. Rhodes, “Opioid Receptors and Endogenous Opioids in Diverse Human and Animal Cancers,” Journal of the National Cancer Institute, Vol. 79, No. 5, November 1987, pp. 1059-1065.
[23]	J. Fogh and G. Trempe, “New Human Tumor Cell Lines,” In: J. Fogh, Ed., Human Tumor Cells In Vitro, Plenum Publishing Corp., New York, 1975, pp. 115-159.
[24]	W. S. Shim, M. Teh, P. O. Mack and R. Ge, “Inhibition of Angiopoietin-1 Expression in Tumor Cells by Antisence RNA Approach Inhibited Xenograft Tumor Growth in Immunodeficient Mice,” International Journal of Cancer, Vol. 94, No. 1, October 2001, pp. 6-15. doi:10.1002/ijc.1428
[25]	I. S. Zagon, S. D. Hytrek, C. M. Lang, J. P. Smith, T. J. McGarrity, Y. Wu and P. J. McLaughlin, “Opioid Growth Factor ([Met5]Enkephalin) Prevents the Incidence and Retards the Growth of Human Colon Cancer,” American Journal of Physiology, Vol. 271, No. 3, Part 2, September 1996, pp. R780-R786.
[26]	P. J. McLaughlin, R. J. Levin and I. S. Zagon, “Opioid Growth Factor (OGF) Inhibits the Progression of Human Squamous Cell Carcinoma of the Head and Neck Transplanted into Nude Mice,” Cancer Letters, Vol. 199, No. 2, September 2003, pp. 209-217. doi:10.1016/S0304-3835(03)00341-0
[27]	I. S. Zagon, S. D. Hytrek, J. P. Smith and P. J. McLaughlin, “Opioid Growth Factor (OGF) Inhibits Human Pancreatic Cancer Transplanted into Nude Mice,” Cancer Letters, Vol. 112, No. 2, January 1997, pp. 167-175. doi:10.1016/S0304-3835(96)04566-1
[28]	K. Yamamoto, Y. Kikuchi, K. Kudoh, J. Hirata, T. Kita and I. Nagata, “Treatment with Paclitaxel Alone, Rather than Combination with Paclitaxel and Cisplatin May be Selective for Cisplatin-Resistant Ovarian Carcinoma,” Japanese Journal of Clinical Oncology, Vol. 30, No. 10, October 2000, pp. 446-449. doi:10.1093/jjco/hyd116
[29]	T. Maffucci, E. Piccolo, A. Cumashi, M. Iezzi, A. M. Riley, A. Saiardi, H. Y. Godage, C. Rossi, M. Broggini, B. V. Potter, P. Innocenti and M. Falasca, “Inhibition of the Phosphatidylinositol 3-Kinase/AKT Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects,” Cancer Research, Vol. 65, No. 18, September 2005, pp. 8339-8349.
[30]	I. S. Zagon and P. J. McLaughlin, “Production and Characterization of Polyclonal and Monoclonal Antibodies to the Zeta (Ζ) Opioid Receptor,” Brain Research, Vol. 630, No. 1-2, December 1993, pp. 295-302.doi:10.1016/0006-8993(93)90669-E
[31]	I. S. Zagon, M. F. Verderame, J. L. Hankins and P. J. McLaughlin, “Overexpression of the Opioid Growth Factor Receptor Potentiates Growth Inhibition in Human Pancreatic Cancer Cells,” International Journal of Oncology, Vol. 30, No. 4, April 2007, pp. 775-783.
[32]	P. J. McLaughlin, M. F. Verderame, J. L. Hankins and I. S. Zagon, “Overexpression of the Opioid Growth Factor Receptor Downregulates Cell Proliferation of Human Squamous Carcinoma Cells of the Head and Neck,” International Journal of Molecular Medicine, Vol. 19, No. 3, March 2007, pp. 421-428.
[33]	A. Bandyopadhyay, F. López-Casillas, S. N. Malik, J. L. Montiel, V. Mendoza, J. Yang and L. Z. Sun, “Antitumor Activity of a Recombinant Soluble Betaglycan in Human Breast Cancer Xenograft,” Cancer Research, Vol. 62, No. 16, August 2002, pp. 4690-4695.
[34]	R. Ravi, B. Mookerjee, Z. M. Bhujwalla, C. H. Sutter, D. Artemov, Q. Zeng, L. E. Dillehay, A. Madan, G. L. Semenza and A. Bedi, “Regulation of Tumor Angiogenesis by P53-Induced Degradation of Hypoxia-Inducible Factor 1alpha,” Genes & Development, Vol. 14, No. 1. January 2000, pp. 34-44.
[35]	T. Egawa-Takata, H. Endo, M. Fujita, Y. Ueda, T. Miyatake, H. Okuyama, K. Yoshino, S. Kamiura, T. Enomoto, T. Kimura and M. Inoue, “Early Reduction of Glucose Uptake after Cisplatin Treatment is a Marker of Cisplatin Sensitivity in Ovarian Cancer,” Cancer Science, Vol. 101, No. 10. October 2010, pp. 2171-2178. doi:10.1111/j.1349-7006.2010.01670.x
[36]	K. L. Wang, Y. C. Yang , J. C. Lai , T. H. Tsai, C. P. Lin, Y. T. Wu, Y. Y. Chen, S. C. Wang and Y. J. Chen, “Comparison in Purity and Antitumor Effect of Brand and Generic Paclitaxel Against Human Ovarian Cancer Cells by an In Vitro Experimental Model,” Drug Development and Industrial Pharmacy, Vol. 36, No. 10. October 2010, pp. 1253-1258.
[37]	C. M. Kurbacher and P. K. Mallmann, “Chemoprotection in Anticancer Therapy: The Emerging Role of Amifostine,” Anticancer Research, Vol. 18, No. 3C, May- June 1998, pp. 2203-2210.
[38]	J. R. Jaglowski, I. S. Zagon, B. C. Stack, M. F. Verderame, A. E. Leure-duPree, J. D. Manning and P. J. McLaughlin, “Opioid Growth Factor Enhances Tumor Growth Inhibition and Increases the Survival of Paclitaxel-Treated Mice with Squamous Cell Carcinoma of the Head and Neck,” Cancer Chemother Pharmacol, Vol. 56, No. 1, July 2005, pp. 97-104.doi:10.1007/s00280-004-0929-4
[39]	M. A. Whiteside, C. J. Piyathilake, T. M. Bushell and G. L. Johanning, “Intrinsic Cisplatin Resistance in Lung and Ovarian Cancer Cells Propagating in Medium Acutely Depleted of Folate,” Nutrition and Cancer, Vol. 54, No. 2, 2006, pp. 274-284. doi:10.1207/s15327914nc5402_14
[40]	C. Rodriguez-Antona, “Pharmacogenomics of Paclitaxel,” Pharmacogenomics, Vol. 11, No. 5, May 2010, pp. 621-623. doi:10.2217/pgs.10.32
[41]	S. F. Bellon, J. H. Coleman and S. J. Lippard, “DNA Unwinding Produced by Site-Specific Intrastrand Cross- Links of the Antitumor Drug Cis-Diamminedichloroplatinum(II),” Biochemistry, Vol. 30, No. 32, August 1991, pp. 8026- 8035.
[42]	G. Chu, “Cellular Responses to Cisplatin; the Roles of DNA-Binding Proteins and DNA Repair,” The Journal of Biological Chemistry, Vol. 269, No. 2, January 1994, pp. 787-790.
[43]	J. Blebea, J. E. Mazo, T. K. Kihara, J. H. Vu, P. J. McLaughlin, R. G. Atnip and I. S. Zagon, “Opioid Grow- th Factor Modulates Angiogenesis,” Journal of Vascular Surgery, Vol. 32, No. 2. August 2000, pp. 364-373. doi:10.1067/mva.2000.107763b
[44]	J. Blebea, J. H. Vu, S. Assadnia, P. J. McLaughlin, R. G. Atnip and I. S. Zagon, “Differential Effects of Vascular Growth Factors on Arterial and Venous Angiogenesis,” Journal of Vascular Surgery, Vol. 35, No. 3, March 2002, pp. 532-538. doi:10.1067/mva.2002.120042
[45]	K. Gach, M. Piestrzeniewicz, J. Fichna, B. Stefanska, J. Szemraj and A. Janecka, “Opioid-Induced Regulation of Mu-Opioid Receptor Gene Expression in the MCF-7 Breast Cancer Cell Line,” Biochemistry and Cell Biology, Vol. 86, No. 3, June 2008, pp. 217-226.doi:10.1139/O08-001
[46]	D. S. Kim, H. Chin and W. A. Klee, “Agonist Regulation of the Expression of the Delta Opioid Receptor in NG108-15 Cells,” FEBS Letters, Vol. 376, No. 1-2, November 1995, pp. 11-14.
[47]	J. P. Smith, R. L. Conter, S. I. Bingaman, H. A. Harvey, D. T. Mauger, M. Ahmad, L. M. Demers, W. B. Stanley, P. J. McLaughlin and I. S. Zagon, “Treatment of Advanced Pancreatic Cancer with Opioid Growth Factor: Phase I,” Anti-Cancer Drugs, Vol. 15, No. 3, March 2004, pp. 203-209. doi:10.1097/00001813-200403000-00003
[48]	J. P. Smith, S. I. Bingaman, D. T. Mauger, H. A. Harvey, L. M. Demers and I. S. Zagon, “Opioid Growth Factor (OGF) Improves Clinical Benefit and Survival in Patients with Advanced Pancreatic Cancer,” Open Access Journal of Clinical Trials, Vol. 2010, No. 2, March 2010, pp. 1-12.